Cardiac biomarkers are the substances that are released into the bloodstream when the heart is stressed or damaged. Suppression of tumorigenicity 2 (ST2) is one such biomarker used to help in measurement of heart failure risk to assess the treatment options. The ST2 biomarker is a member of the interleukin-1 receptor family biomarker. It is a strong predictor and most promising biomarker for both chronic and acute heart failure.

Market Analysis and Insights: Global ST2 Biomarker Market
The global ST2 Biomarker market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global ST2 Biomarker market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global ST2 Biomarker market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global ST2 Biomarker market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global ST2 Biomarker market.

Global ST2 Biomarker Scope and Market Size
ST2 Biomarker market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global ST2 Biomarker market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
ELISA Based ST2 Biomarker
Immunochromatography Based ST2 Biomarker

Segment by Application
Hospitals
Diagnostic Centres
Ambulatory Surgical Centres
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
Thermo Fisher Scientific
BD
Roche
Abbott
Siemens
Bio-Rad
BioMerieux